Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

NCT04680377 · clinicaltrials.gov ↗

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

NSCLC, Stage III
Locally Advanced Lung Carcinoma

Sponsor

Jun Zhang, MD, PhD

Collaborators

[object Object]